Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report-Reference-Cited by-同舟云学术

Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer: A Case Report

Published:2023 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Tanaka Takaaki¹,Taoka Masataka¹,Makimoto Go¹,Ninomiya Kiichiro²,Higo Hisao¹,Fujii Masanori¹,Ichihara Eiki¹,Ohashi Kadoaki¹,Hotta Katsuyuki³,Tabata Masahiro⁴,Maeda Yoshinobu⁵

Affiliation:

1. Department of Respiratory Medicine, Okayama University Hospital, Japan

2. Center for Comprehensive Genomic Medicine, Okayama University Hospital, Japan

3. Center for Innovative Clinical Medicine, Okayama University Hospital, Japan

4. Center for Clinical Oncology, Okayama University Hospital, Japan

5. Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_2429-23/_pdf

Reference15 articles.

1. 1. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA oncology 4: 1721-1728, 2018.

2. 2. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. J Clin Oncol 39: 3978-3992, 2021.

3. 3. Holtzman NG, Xie H, Bentzen S, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-oncology 23: 112-121, 2021.

4. 4. de Groot PM, Arevalo O, Shah K, et al. Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists. Radiographics 42: 176-194, 2022.

5. 5. Ceschi A, Noseda R, Palin K, Verhamme K. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database. Frontiers in pharmacology 11: 557, 2020.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytokine release syndrome following COVID-19 infection during treatment with nivolumab for cancer of esophagogastric junction carcinoma: a case report and review;International Journal of Emergency Medicine;2024-09-02

2. Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS;Expert Opinion on Drug Safety;2024-07-29

3. Glofitamab-Associated Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Serial Seizures and Responding Positively to Antiseizure Drugs and Anakinra: A Case Report;Cureus;2024-05-22

4. Fever of unknown origin associated with immune checkpoint inhibitors;Frontiers in Immunology;2024-03-12

5. Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report;Journal of Thoracic Oncology;2023-11